Skip to main content
SpringerLink
Log in

Biochemische und hämodynamische Effekte von Zink-Protamin-Glucagon am Menschen

Biochemical and haemodynamic effects of zinc-protamin-glucagon in man

  • Originalien
  • Published:
Klinische Wochenschrift Aims and scope Submit manuscript

Summary

The subcutaneous injection of 5 mg of zincprotamine-glucagon results in a 40% increase of blood glucose within 1 hour; this elevated level is maintained for several hours. The activation of lipase after the administration of glucagon in patients is insignificant and of short duration (only 7% rise of plasma FFA 10 minutes after injection) and is followed by an insulin-induced fall of plasma FFA by 50% within 6 hours. There is a concomitant, statistically significant rise in serum insulin.

Haemodynamic measurements following a single dose of 5 mg of zinc-protamine-glucagon revealed only a statistically non significant 16.7% rise in LVdp/dt max, after 15 minutes, the other parameters remaining essentially unchanged.

The possible elinical significance of these glucagon effects is discussed.

Zusammenfassung

Zink-Protamin-Glucagon zeigt bei s.c.-Injektion in einer Dosis von 5 mg einen deutlichen, aber protrahierten Anstieg des Blutzuckers um rund 40% innerhalb 1 Std und behält dieses erhöhte Niveau durch mehrere Stunden bei. Die Lipase-Aktivitätssteigerung nach Glucagon ist beim Menschen nur kurzfristig und unbedeutend [rund 7% ige Zunahme der freien Fettsäuren (FFS) 10 min p. inj.], sie wird von einem insulininduzierten Abfall der FFS um rund 50% im Laufe von 6 Std gefolgt. Die Zunahme der Insulinspiegel im Serum ist zwar statistisch signifikant, erreicht aber nicht das Ausmaß der von der intravenösen Verabreichung bekannten Veränderungen.

Die hämodynamischen Effekte einer Einzeldosis von 5 mg Zink-Protamin-Glucagon sind nicht eindeutig und lassen lediglich eine nicht signifikante Zunahme von LVdp/dt max um 16,7% nach 15 min erkennen, während alle anderen Parameter im wesentlichen unverändert bleiben.

Die mögliche klinische Bedeutung dieser Glucagoneffekte wird diskutiert.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Literatur

  1. Avenhaus, H., Lüderitz, B., Strauer, B. E., Bolte, H. D., Riecker, G.: Kardiale Wirkungen von Glucagon. Dtsch. med. Wschr.96, 702–707 (1971)

    Google Scholar 

  2. Bernard, S., Duchesse, G., Herman, B.: Utilisation du Glucagon en perfusion continue dans le traîtement des états de choc. Presse méd.79, 267–270 (1971)

    Google Scholar 

  3. Bianco, J. A., Shanahan, A., Ostheimer, W., Guyton, A., Powell, J., Jr., Daggett, M.: Effects of glucagon on myocardial oxygen consumption and potassium balance. Amer. J. Physiol.221, 626–631 (1971)

    PubMed  Google Scholar 

  4. Bourassa, M. G., Eibar, J., Campeau, L.: Effects of glucagon on myocardial metabolism in patients with and without coronary artery disease. Circulation42, 53–60 (1970)

    PubMed  Google Scholar 

  5. Brogan, E., Kozonis, C., Overy, C.: Glucagon therapy in heart failure. Lancet1969I, 482–484

  6. Cohn, K. E., Agmon, J., Gamble, O. W.: The effect of glucagon on arrhythmias due to digitalis toxicity. Amer. J. Cardiol.25, 683–689 (1970)

    PubMed  Google Scholar 

  7. Dolgin, M.: Treatment of cardiac failure with glucagon. Amer. Heart J.79, 843 (1970)

    PubMed  Google Scholar 

  8. Dole, V. P., Meinertz, H.: Microdetermination of long-chain fatty acids in plasma and tissues. J. biol. Chem.235, 2595–2599 (1960)

    PubMed  Google Scholar 

  9. Editorial: Glucagon. Brit. med. J.1971II, 524–525

  10. Ellis, S., Beckett, S. B.: Mechanism of the potassium mobilizing action of epinephrine and glucagon. J. Pharmacol. exp. Ther.142, 318 (1963)

    PubMed  Google Scholar 

  11. Entman, M. L., Levey, G. S., Epstein, S. E.: Mechanism of action of epinephrine and glucagon on canine heart: Evidence for increase in sarcotubular calcium stores mediated by cyclic 3′,5′-AMP. Circulat. Res.25, 429–438 (1969)

    PubMed  Google Scholar 

  12. Epstein, S. E., Levey, G. S., Skelton, C. L.: Adenyl cyclase and cyclic AMP: Biochemical links in the regulation of myocardial contractility. Circulation43, 437–450 (1971)

    PubMed  Google Scholar 

  13. Epstein, S. E., Skelton, C. L., Levey, G. S., Entman, M. L.: Adenyl cyclase and myocardial contractility. Ann. intern. Med.72, 561–578 (1970)

    Google Scholar 

  14. Farah, A., Tuttle, R.: Studies on the pharmacology of glucagon. J. Pharmacol. exp. Ther.129, 49 (1960)

    PubMed  Google Scholar 

  15. Friedman, M., Byers, S. O., Rosenman, R. H.: Effect of glucagon on blood-cholesterol levels in rats. Lancet1971II, 464–466

  16. Glick, G., Parmely, W. W., Wechsler, A. S., Sonnenblick, E. H.: Glucagon: Its enhancement of cardiac performance in the cat and dog and persistence of its inotropic action despite beta-receptor blockade with propranolol. Circulat. Res.22, 789–799 (1968)

    PubMed  Google Scholar 

  17. Gold, H. K., Prindle, K. H., Levey, G. S., Epstein, S. E.: Effects of experimental heart failure on the capacity of glucagon to augment myocardial contractility and active adenyl cyclase. Clin. Invest.49, 999–1006 (1970)

    Google Scholar 

  18. Goldschlager, N., Robin, E., Cowan, Ch. M., Leb, G., Bing, R. J.: The effect of glucagon on the coronary circulation in man. Circulation40, 829–837 (1969)

    Google Scholar 

  19. Gudbjarnason, S., Fenton, J. C., Wolf, L. P., Bing, R. J.: Stimulation of reparative processes following experimental myocardial infarction. Arch. intern. Med.118, 33–40 (1966)

    PubMed  Google Scholar 

  20. Hagen, J. H.: Effect of glucagon on the metabolism of adipose tissue. Biol. Chem.236, 1023–1027 (1961)

    Google Scholar 

  21. Hoack, H. C., Connor, W. E., Warner, E. D.: Toxic effects of glucagon-induced acute lipid mobilization in geese. J. clin. Invest.47, 2701–2710 (1968)

    PubMed  Google Scholar 

  22. Kaindl, F., Kühn, P., Ogris-Kautek, E., Pfeiffer, G., Pilgerstorfer, H. W., Schatz, H.: Zur Herzwirkung des Glucagons beim Menschen. Festschrift Aloisio Condorelli 345–356 (1969)

  23. Kaindl, F., Kühn, P., Schatz, H.: L'entraînement physique à la phase aigue de l'infarctus du myocarde. Ann. Cardiol. Angéiol.20, 147–150 (1971)

    Google Scholar 

  24. Katz, R. L., Hinds, L., Mills, C. J.: Ability of glucagon to produce cardiac stimulation without arrhythmias in Halothane-anaesthetized animals. Brit. J. Anaesth.41, 547–578 (1971).

    Google Scholar 

  25. Kones, R. J., Phillips, J. H.: Glucagon in congestive heart failure. Chest59, 392–397 (1971)

    PubMed  Google Scholar 

  26. Kühn, P.: Therapie der Herzinsuffizienz mit Zink-Protamin-Glucagon (im Druck)

  27. Kumar, R., Sharma, R. K., Molokhia, F. A., Norman, J. C., Inamdar, A. N., Messer, J. V., Abelmann, W. H., Hood, W. B., Jr.: Experimental myocardial infarction: X. efficacy of glucagon in the acute and healing phase in intact conscious dogs: Effects on hemodynamics and myocardial oxygen consumption. Circulation45, 55–64 (1972)

    PubMed  Google Scholar 

  28. Kurien, V. A., Oliver, M. F.: Serum free fatty acids after acute myocardial infarction and cerebral vascular occlusion. Lancet1966II, 122–127

  29. La Raia, P., Craig, R., Reddy, W.: Glucagon: Biochemical mechanisms and contractility effects in the heart. Amer. J. Cardiol.21, 107 (1968)

    Google Scholar 

  30. Lawrence, A. M.: Glucagon provocative test for pheochromocytoma. Ann. intern Med.66, 1091–1096 (1967)

    PubMed  Google Scholar 

  31. Levey, G. S., Prindle, K. H., Jr., Epstein, S. E.: Effects of glucagon on adenyl cyclase activity in the left and right ventricles and liver in experimentally produced isolated right ventricular failure. Molecular and Cellular Cardiology1, 403–410 (1970)

    Google Scholar 

  32. Lipski, J. I., Kaminsky, D. M., Donoso, E., Friedberg, C. K.: The electrophysiologic properties of glucagon on the normal canine heart. Amer. J. Cardiol.23, 124–125 (1969)

    Google Scholar 

  33. Lucchesi, B. R.: Cardiac actions of glucagon. Circulat. Res.22, 777–787 (1968)

    PubMed  Google Scholar 

  34. Lüderitz, B., Avenhaus, H., Seufert, C. D.: Zur Wirkung von Glucagon auf die extrazelluläre Kaliumkonzentration — Messungen in Aorta, Lebervene und Sinus coronarius des Menschen. Klin. Wschr.49, 1334–1337 (1971)

    PubMed  Google Scholar 

  35. Lüderitz, B., Bolte, H. D.: The electrophysiological effects of glucagon and epinephrine on the ventricular myocardium (Abstract). Europ. Soc. Clin. Invest.: Fifth Annual Meeting 1971

  36. Manchester, J. H., Parmley, W. W., Matloff, J. M., Leidtke, A. J., Laraia, P., Herman, M. V., Sonnenblick, E. H., Gorlin, R.: Effects of glucagon on myocardial oxygen consumption and coronary blood flow in man and dog. Circulation41, 579–588 (1970)

    PubMed  Google Scholar 

  37. Melani, F., Ditschuneit, H., Bertelt, K. M., Friedrich, H., Pfeiffer, E.: Über die radioimmunologische Bestimmung von Insulin im Blut. Klin. Wschr.43, 1000–1004 (1965)

    PubMed  Google Scholar 

  38. Moir, Th. W., Nayler, W. G.: Coronary vascular effects of glucagon in the isolated dog heart. Circulat. Res.26, 29–34 (1970)

    PubMed  Google Scholar 

  39. Murad, F.: Effects of glucagon on heart. New Engl. Med.279, 434–435 (1968)

    Google Scholar 

  40. Nord, J., Fontanes, A. L., Williams, J. F.: Treatment of congestive heart failure with glucagon. Ann. intern. Med.72, 649–653 (1970)

    PubMed  Google Scholar 

  41. Oliver, M. F.: The relationship of serum free fatty acids to arrhythmias and death. In: D. G. Julian and M. F. Oliver, Acute myocardial infarction, p. 251. Edinburgh and London: E. & S. Livingstone Ltd 1968

    Google Scholar 

  42. Opie, L. H.: Acute metabolic response in myocardial infarction. Brit. Heart. J.33, Suppl. 129–137 (1971)

    PubMed  Google Scholar 

  43. Parmley, W. W., Glick, G., Sonnenblick, E. H.: Cardiovascular effects of glucagon in man. New Engl. J. Med.279, 12–17 (1968)

    PubMed  Google Scholar 

  44. Parmley, W. W., Sonnenblick, E. H.: Glucagon: A new agent in cardiac therapy. Amer. J. Cardiol.27, 298–303 (1971)

    PubMed  Google Scholar 

  45. Pentzer, J. G., Schuhmacher, H. B., Jr.: Coronary sinus flow-influence of glucagon and hypertonic dextrose and saline. Arch. Surg.85, 879 (1962)

    PubMed  Google Scholar 

  46. Polumbo, R. A., Leighton, R. F., Weissler, A. M.: Efficacy of isoproterenol-glucagon-infusion in patients with heart disease. Circulation43, 786–791 (1971)

    PubMed  Google Scholar 

  47. Regan, T. J., Lehan, P. H., Henneman, D. H., Behar, A., Hellems, H. K.: Myocardial metabolic and contractile response to glucagon and epinephrine. J. Lab. clin. Med.63, 638–647 (1964)

    PubMed  Google Scholar 

  48. Robert, M., Humair, L.: Cardiotone Wirkung von Glucagon. Schweiz. med. Wschr.100, 1345–1352 (1970)

    PubMed  Google Scholar 

  49. Rowe, G. R.: Systemic and coronary hemodynamic effects of glucagon. Amer. J. Cardiol.25, 670–674 (1970)

    PubMed  Google Scholar 

  50. Schmidt, F. H.: Enzymatische Methoden zur Bestimmung von Blut- und Harnzucker unter Berücksichtigung von Vergleichsuntersuchungen mit klassischen Methoden. Internist (Berl.)4, 554–559 (1963)

    Google Scholar 

  51. Steiner, Ch., Wit, A. L., Damato, A. N.: Effects of glucagon on atrioventricular conduction and ventricular automaticity in dogs. Circulat. Res.24, 167–177 (1969)

    PubMed  Google Scholar 

  52. Tarding, F., Nielsen, P., Pingel, M., Vølund, A.: Biological and chemical properties of two glucagon preparations with prolonged action. Europ. J. Pharmacol.7, 206–210 (1969)

    Google Scholar 

  53. Whitehouse, F. W., James, T. N.: Chronotropic action of glucagon on the sinus node. Proc. Soc. exp. Biol. (N.Y.)122, 823–826 (1966)

    Google Scholar 

  54. Whitsitt, L. S., Lucchesi, B. R.: Effects of beta-receptor blockade and glucagon on the atrioventricular transmission system in the dog. Circulat. Res.23, 585–595 (1968)

    PubMed  Google Scholar 

  55. Wilcken, D. E., Lvoff, R.: Glucagon in resistant heart failure and cardiogenic shock. Lancet1970II, 1315–1318

  56. Wolson, S. K., Jr., Ellis, S.: Effects of glucagon on plasma potassium. Proc. Soc. exp. Biol. (N.Y.)91, 226–229 (1956)

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Kardiologische Universitätsklinik Wien, Austria

    P. Kühn, P. Holzhey, M. Niederberger, H. Fritzsche, A. Kroiss, B. Brenner & F. Kaindl

  2. II. Medizinische Universitätsklinik Wien, Austria

    P. Kühn, P. Holzhey, M. Niederberger, H. Fritzsche, A. Kroiss, B. Brenner & F. Kaindl

Authors
  1. P. Kühn
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. P. Holzhey
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M. Niederberger
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. H. Fritzsche
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. A. Kroiss
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. B. Brenner
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. F. Kaindl
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kühn, P., Holzhey, P., Niederberger, M. et al. Biochemische und hämodynamische Effekte von Zink-Protamin-Glucagon am Menschen. Klin Wochenschr 51, 951–956 (1973). https://doi.org/10.1007/BF01468250

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01468250

Key words

Schlüsselwörter

Search

Navigation